Prevalence of positive FDG-PET findings in patients with high CEA levels

Annals of Nuclear Medicine

Volumn 24, Issue 6, 2010, Pages 433-439

  Suga, Tsuyoshi ^a   Nakamoto, Yuji ^a   Saga, Tsuneo ^b   Higashi, Tatsuya ^a   Hara, Tadashi ^a   Ishizu, Koichi ^a   Nishizawa, Hidemitsu ^a   Togashi, Kaori ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Cancer; CEA; FDG; PET; Screening

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ESOPHAGUS CANCER; FEMALE; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PANCREAS CANCER; PLEURA PLAQUE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; BLOOD; DIAGNOSTIC USE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDY; SCINTISCANNING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 77955468730     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-010-0387-5     Document Type: Article

References (28)

1. DM Goldenberg AM Neville AC Carter VL Go ED Holyoke KJ Isselbacher, et al. 1981 CEA (carcinoembryonic antigen): its role as a marker in the management of cancer J Cancer Res Clin Oncol 101 239 242 10.1007/BF00410109 1:CAS:528:DyaL3MXmtVSit78%3D 7309778
2. RA Stockley J Shaw AG Whitfield TP Whitehead CA Clarke D Burnett 1986 Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions Thorax 41 17 24 10.1136/thx.41.1.17 1:STN:280:DyaL283gvVyrug%3D%3D 3704962
3. I Fukuda M Yamakado H Kiyose 1998 Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services J Med Syst 22 89 93 10.1023/A:1022643102208 1:STN:280:DyaK1c3jtlSjtA%3D%3D 9571515 (Pubitemid 28183525)
4. GF Blackburn HP Shah JH Kenten J Leland RA Kamin J Link, et al. 1991 Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics Clin Chem 37 1534 1539 1:CAS:528: DyaK3MXmsFWmu7w%3D 1716534
5. Y Kim S Lee S Park H Jeon W Lee JK Kim, et al. 2003 Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen Ann Clin Lab Sci 33 32 38 12661896
6. YY Shen JA Liang YK Chen CY Tsai CH Kao 2006 Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan Hepatogastroenterology 53 348 350 16795969
7. M Suárez MJ Pérez-Castejón A Jiménez M Domper G Ruiz R Montz, et al. 2002 Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers Q J Nucl Med 46 113 121 12114874
8. JW de Groot TP Links PL Jager T Kahraman JT Plukker 2004 Impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer Ann Surg Oncol 11 786 794 10.1245/ASO.2004.10.015 15289241 (Pubitemid 40486694)
9. H Kitano Y Magata A Tanaka T Mukai Y Kuge K Nagatsu, et al. 2001 Performance assessment of O-18 water purifier Ann Nucl Med 15 75 78 10.1007/BF03012137 1:CAS:528:DC%2BD3MXjvValsbY%3D 11355788
10. RS Brown SJ Fisher RL Wahl 1993 Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-d-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma J Nucl Med 34 75 82 1:STN:280:DyaK3s7hsFyitQ%3D%3D 8418275
11. RS Brown JY Leung SJ Fisher KA Frey SP Ethier RL Wahl 1996 Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake J Nucl Med 37 1042 1047 1:STN:280:DyaK28zgtVersw%3D%3D 8683298
12. RS Brown JY Leung PV Kison KR Zasadny A Flint RL Wahl 1999 Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer J Nucl Med 40 556 565 1:STN:280:DyaK1M3isV2iuw%3D%3D 10210213
13. K Higashi AC Clavo RL Wahl 1993 Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake J Nucl Med 34 414 419 1:CAS:528:DyaK3sXks12iu7k%3D 8441032
14. MY Choi KM Lee JK Chung DS Lee JM Jeong JG Park, et al. 2005 Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer Ann Nucl Med 19 123 129 10.1007/BF03027391 15909492
15. GY Locker S Hamilton J Harris JM Jessup N Kemeny JS Macdonald, et al. 2006 ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol 24 5313 5327 10.1200/JCO.2006.08.2644 1:CAS:528:DC%2BD28XhtlemurfN 17060676 (Pubitemid 46631379)
16. F Guadagni P Ferroni S Carlini S Mariotti A Spila S Aloe, et al. 2001 A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study Clin Cancer Res 7 2357 2362 1:CAS:528:DC%2BD3MXmsVOmt7k%3D 11489813
17. C Tondini DF Hayes R Gelman IC Henderson DW Kufe 1988 Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer Cancer Res 48 4107 4112 1:STN:280:DyaL1c3ltlaruw%3D%3D 3164256
18. B Mroczko M Kozłowski M Groblewska M Łukaszewicz J Nikliński W Jelski, et al. 2008 The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients Clin Chim Acta 389 61 66 10.1016/j.cca.2007.11.023 1:CAS:528:DC%2BD1cXhsVyisb4%3D 18155162
19. Aide N, Huchet V, Switsers O, Heutte N, Delozier T, Hardouin A et al. Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun. 2007;28:267-72.
20. YK Chen DS Hsieh CS Liao CH Bai CT Su YY Shen, et al. 2005 Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence Anticancer Res 25 4719 4725 16334166
21. M Murakami T Miyamoto T Iida H Tsukada M Watanabe M Shida, et al. 2006 Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer Int J Gynecol Cancer 16 Suppl 1 99 107 10.1111/j.1525-1438.2006.00471.x 16515575
22. J Jiménez-Bonilla A Maldonado S Morales A Salud M Zomeño J Román, et al. 2000 Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels Clin Positron Imaging 3 231 236 10.1016/S1095-0397(01)00053-X 11378435
23. WC Chang YC Hung CH Kao RF Yen YY Shen CC Lin 2002 Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker Neoplasma 49 329 333 1:STN:280:DC%2BD38npslSnug%3D%3D 12458332
24. WC Chang YC Hung CC Lin YY Shen CH Kao 2004 Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels-a preliminary report Cancer Invest 22 180 184 10.1081/CNV- 120030205 1:CAS:528:DC%2BD2cXjtl2qtL0%3D 15199599 (Pubitemid 38725171)
25. ML Maussier V Valenza G Schinco G Galli 1990 AFP, CEA, CA 19-9 and TPA in hepatocellular carcinoma Int J Biol Markers 5 121 126 1:STN:280: DyaK3M7ktVSltA%3D%3D 1704905
26. GL Grazi A Mazziotti C Legnani E Jovine R Miniero A Gallucci, et al. 1995 The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin Liver Transpl Surg 1 249 255 10.1002/lt.500010410 1:STN:280:DyaK1c%2FgtlWkuw%3D%3D 9346575
27. G Antoch N Saoudi H Kuehl G Dahmen SP Mueller T Beyer, et al. 2004 Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET J Clin Oncol 22 4357 4368 10.1200/JCO.2004.08.120 15514377 (Pubitemid 41185156)
28. Y Nakamoto S Sakamoto T Okada M Senda T Higashi T Saga, et al. 2007 Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer AJR Am J Roentgenol 188 257 267 10.2214/AJR.05.0708 17179375 (Pubitemid 46012519)